Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX660 in Advanced Solid Tumors and Lymphomas
NCT02503423Phase 2Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Jul 2015
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of tolinapant in solid tumor, lymphoma, head and neck squamous cell carcinoma (HNSCC) and 4 more (9 arms), sponsored by Taiho Oncology. Primary endpoints: Number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results up to 78 months, Objective Response Rate up to 84 months and 1 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
tolinapant
03
Conditions
solid tumorlymphomahead and neck squamous cell carcinoma (HNSCC)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02503423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503423.